PAREXEL announces launch of new regulatory outsourcing service line for life sciences industry

PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, today announced the launch of a new service line designed to provide a focused, market-driven approach to regulatory outsourcing services in the life sciences industry, with a primary emphasis on post-approval regulatory activities.

Through PAREXEL Regulatory Outsourcing Services, the Company will customize these services for clients based upon their unique needs and business challenges by combining expertise, operational approaches and technology.  The service line will reside within the PAREXEL Consulting business segment.

"With the ever-changing regulatory environment, pharmaceutical companies face new challenges that need to be addressed with efficiency and cost in mind," said Mark A. Goldberg, M.D., President and Chief Operating Officer, PAREXEL. "PAREXEL is uniquely positioned to provide this new service offering, given our regulatory expertise, global operational capabilities and information management technology. Clients will now be able to outsource significant portions of their regulatory activities to a trusted partner in a cost-effective manner."

"Regulatory outsourcing is growing increasingly important in the market as more and more companies rely on outsourcing to help them with the complex task of managing their regulatory needs, especially the regulatory maintenance of their marketed products," said Rick Riegel, Corporate Vice President and new head of the PAREXEL Regulatory Outsourcing Services line. "This service offering provides a unique solution that addresses new pressures felt by our clients, allowing them to become more efficient in the area of regulatory operations and affairs."

The launch of PAREXEL Regulatory Outsourcing Services broadens PAREXEL's portfolio of regulatory information management solutions.  In 2012, PAREXEL's acquisition of LIQUENT, Inc. strengthened its regulatory capabilities by adding a robust information technology platform, LIQUENT InSight®.  

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Parexel. (2019, June 20). PAREXEL announces launch of new regulatory outsourcing service line for life sciences industry. News-Medical. Retrieved on December 24, 2024 from https://www.news-medical.net/news/20140219/PAREXEL-announces-launch-of-new-regulatory-outsourcing-service-line-for-life-sciences-industry.aspx.

  • MLA

    Parexel. "PAREXEL announces launch of new regulatory outsourcing service line for life sciences industry". News-Medical. 24 December 2024. <https://www.news-medical.net/news/20140219/PAREXEL-announces-launch-of-new-regulatory-outsourcing-service-line-for-life-sciences-industry.aspx>.

  • Chicago

    Parexel. "PAREXEL announces launch of new regulatory outsourcing service line for life sciences industry". News-Medical. https://www.news-medical.net/news/20140219/PAREXEL-announces-launch-of-new-regulatory-outsourcing-service-line-for-life-sciences-industry.aspx. (accessed December 24, 2024).

  • Harvard

    Parexel. 2019. PAREXEL announces launch of new regulatory outsourcing service line for life sciences industry. News-Medical, viewed 24 December 2024, https://www.news-medical.net/news/20140219/PAREXEL-announces-launch-of-new-regulatory-outsourcing-service-line-for-life-sciences-industry.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
PAREXEL launches Patient Innovation Center to improve drug development process